HPV
HPV
GARDASIL 9 · CERVARIX
One, two or three doses depending on your age and health. Every product below is a Health Canada authorized vaccine; every schedule comes from the Canadian Immunization Guide.
Products authorized in Canada
Brand names and DINs (Drug Identification Numbers) as Health Canada's Drug Product Database lists them. The product monograph is the manufacturer's full prescribing information approved by Health Canada.
| Product | DIN | What it is | Presentation and age | Official information |
|---|---|---|---|---|
| GARDASIL 9 | 02437058 | 9-valent HPV L1 protein (types 6, 11, 16, 18, 31, 33, 45, 52, 58) | 0.5 mL · suspension · intramuscular · 9 to 45 years | Product guideHealth Canada recordProduct monograph (PDF) |
| CERVARIX | 02342227 | Bivalent HPV L1 protein (types 16, 18) | 0.5 mL · suspension · intramuscular · females 9 to 45 years | Product guideHealth Canada recordProduct monograph (PDF) |
Pregnancy and breastfeeding
Pregnancy
Can be offered in pregnancy; it is usually deferred until after, and a dose given before pregnancy was known is not a concern.
Breastfeeding
Use if indicated.
Source: Immunization in pregnancy and breastfeeding: Canadian Immunization Guide — Chapter updated August 2026. Live vaccines are generally contraindicated in pregnancy; routinely recommended vaccines can be given while breastfeeding unless the chapter says otherwise.
How many doses
The schedules the Canadian Immunization Guide describes for this vaccine. Which one applies depends on age, health and product — use the dose planner to see the dates for your situation.
| Schedule | Doses | Who it is for | Products |
|---|---|---|---|
| HPV — ages 9 to 20, one dose One dose of 9-valent HPV vaccine for people who start at age 9 through 20. | 1 dose | Age at the first dose decides the schedule. A 2-dose schedule may be considered on an individual basis. People who are immunocompromised or living with HIV need three doses. | GARDASIL 9 |
| HPV — ages 9 to 20, optional two doses Optional two-dose schedule, at least 24 weeks apart. | 2 doses | May be considered individually for people who start at age 9 through 20, after discussion with a healthcare provider. The two doses must be at least 24 weeks apart. | GARDASIL 9 |
| HPV — ages 21 to 26, two doses Two doses of 9-valent HPV vaccine at least 24 weeks apart. | 2 doses | Recommended for people 21 through 26 years of age: two doses at least 24 weeks (6 months) apart. | GARDASIL 9 |
| HPV — age 27 and older, two doses after a shared decision Two doses at least 24 weeks apart, decided with a healthcare provider. | 2 doses | At 27 years and older, HPV vaccination is a shared decision with a healthcare provider (GARDASIL 9 is authorized to 45 years). When given: two doses at least 24 weeks apart. | GARDASIL 9 |
| HPV — weakened immune system or HIV, three doses Three doses of 9-valent HPV vaccine at months 0, 2 and 6. | 3 doses | For people 9 years and older who are immunocompromised or living with HIV, regardless of age. Minimum intervals: 4 weeks between doses 1 and 2, 12 weeks between doses 2 and 3, and 24 weeks between doses 1 and 3. | GARDASIL 9 |
| HPV (CERVARIX, bivalent) — three doses Three doses of bivalent HPV vaccine at months 0, 1 and 6. | 3 doses | CERVARIX (HPV2) is authorized for females 9 to 45 years of age. The 9-valent vaccine is the preferred product in Canada; use this schedule only when CERVARIX is the product actually given or the series was started on it. | CERVARIX |
Sources
- Human papillomavirus (HPV) vaccines: Canadian Immunization Guide — Chapter revised July 2024
- Health Canada Drug Product Database — product records and monographs
Clinical rules reviewed on 2026-09-27. General information from public Canadian guidance; a personal assessment is needed for treatment decisions. Care365 does not decide whether a vaccine is publicly funded in Ontario.